Literature DB >> 7636647

Humoral immunity in DiGeorge syndrome.

A K Junker1, D A Driscoll.   

Abstract

OBJECTIVE: To assess humoral immunity after immunization and natural infection in patients with clinical manifestations of the DiGeorge anomalad.
DESIGN: Retrospective review of cases.
SETTING: Ambulatory immunology clinic of a tertiary care teaching hospital. PATIENTS: The 13 patients had a symptom complex including congenital heart disease, characteristic facies of the DiGeorge anomalad, possible hypocalcemia, and thymic hypoplasia or aplasia. Molecular and cytogenic studies of 12 patients demonstrated that all had 22q11 microdeletions.
METHODS: Serial studies included lymphocyte population enumeration by flow cytometry, lymphocyte proliferation assays with the mitogens phytohemagglutinin and pokeweed mitogen and Staphylococcus aureus, and immunoglobulin quantitation. Specific antibody studies included virus neutralization assays for poliovirus antibodies, and enzyme-linked immunosorbent assay for diphtheria, tetanus, measles, rubella, varicella-zoster virus (VZV), and cytomegalovirus (CMV) antibodies. Avidity of rubella, VZV, and CMV antibodies was tested by enzyme-linked immunosorbent assay modified to include a mild protein denaturant in the first wash after incubation with sera.
RESULTS: All patients had a CD3+ cell count greater than 0.500 x 10(9)/L and a CD4+ cell count greater than 0.350 x 10(9)/L). One patient had low proliferation responses to S. aureus, and one to phytohemagglutinin and pokeweed mitogen. Immunoglobulin levels, compared with those in age-related control subjects, were normal except that two patients had transient, borderline low IgG levels and two had elevated IgA levels. Specific antibody tests showed (No. of patients with positive results/No. tested) the following: diphtheria (13/13); tetanus (13/13); poliomyelitis caused by polio virus type 1 (5/9), type 2 (9/9), and type 3 (8/9); measles (11/13); rubella (11/13); and infection with VZV (5/5) and CMV (7/13). There were no significant differences in antibody avidity results between patients and control subjects for rubella (mean avidity index, 83.5 +/- 8.79 vs 85 +/- 17.6), VZV (81.6 +/- 3.98 vs 65.1 +/- 12.38), or CMV (69.3 +/- 22.31 vs 73.3 +/- 12.46).
CONCLUSIONS: Patients with "partial" DiGeorge anomalad, defined by clinical and immunologic criteria, can be immunized and for the most part can generate good antibody responses.

Entities:  

Mesh:

Year:  1995        PMID: 7636647     DOI: 10.1016/s0022-3476(95)70300-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  R Zemble; E Luning Prak; K McDonald; D McDonald-McGinn; E Zackai; K Sullivan
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

2.  Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.

Authors:  Yiwa Suksawat; Achara Sathienkijkanchai; Jittima Veskitkul; Orathai Jirapongsananuruk; Nualanong Visitsunthorn; Pakit Vichyanond; Punchama Pacharn
Journal:  J Clin Immunol       Date:  2017-04-20       Impact factor: 8.317

Review 3.  Immunological aspects of 22q11.2 deletion syndrome.

Authors:  A R Gennery
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

4.  Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  C A Smith; D A Driscoll; B S Emanuel; D M McDonald-McGinn; E H Zackai; K E Sullivan
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

5.  Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  K E Sullivan; D McDonald-McGinn; D A Driscoll; B S Emanuel; E H Zackai; A F Jawad
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

6.  T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome.

Authors:  M Pierdominici; M Marziali; A Giovannetti; A Oliva; R Rosso; B Marino; M C Digilio; A Giannotti; G Novelli; B Dallapiccola; F Aiuti; F Pandolfi
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

Review 7.  Immunodeficiencies Associated with Abnormal Newborn Screening for T Cell and B Cell Lymphopenia.

Authors:  Soma Jyonouchi; Artemio M Jongco; Jennifer Puck; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2017-03-28       Impact factor: 8.317

8.  Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome.

Authors:  A R Gennery; D Barge; J J O'Sullivan; T J Flood; M Abinun; A J Cant
Journal:  Arch Dis Child       Date:  2002-06       Impact factor: 3.791

Review 9.  DiGeorge syndrome/chromosome 22q11.2 deletion syndrome.

Authors:  K E Sullivan
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

10.  A prospective study of influenza vaccination and a comparison of immunologic parameters in children and adults with chromosome 22q11.2 deletion syndrome (digeorge syndrome/velocardiofacial syndrome).

Authors:  Abbas F Jawad; Eline Luning Prak; Jean Boyer; Donna M McDonald-McGinn; Elaine Zackai; Kenyetta McDonald; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2011-08-24       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.